Company: TAK
Filing Date: 2025-06-25
Form Type: 20-F
Source: 0001395064-25-000095
Chunk: 118

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-06-25
Form: 20-F
Item: Item 5
Chunk 118
---
 a favorable resolution of tax contingencies.

Core EPS

Core EPS was JPY 491 (JPY +7 and +1.5% AER, -4.3% CER).

Table of Contents

Fiscal Year Ended March 31, 2024 compared with the Fiscal Year Ended March 31, 2023

                                                                          Billion JPY or percentage                                                                                         
                                                                          For the fiscal year ended                                           AER                                      CER  
                                                                          March 31,                                                                                                         
                                                                          2023                                         2024                   Amount of Change      % Change      % Change  
 ────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
  Core revenue                                                            ¥                              4,027.5          ¥      4,263.8      ¥                          5.9           1.5  
  Core operating profit                                                                                  1,188.4                 1,054.9      (133.5)                 (11.2)        (13.3)  
  Core net profit for the year                                            866.4                                       756.9                   (109.5)                 (12.6)        (15.0)  
  Core net profit for the year attributable to owners of the Company      866.4                                       756.8                   (109.6)                 (12.6)        (15.0)  
  Core EPS (yen)                                                          558                                           484                   (75)                    (13.4)        (15.7)  

Core Revenue

Core Revenue for the fiscal year ended March 31, 2024 was JPY 4,263.8 billion (JPY +236.3 billion and +5.9% AER, +1.5% CER). The increase was attributable to favorable foreign exchange rates and growth from business momentum primarily led by Takeda’s Growth and Launch Products* which totaled JPY 1,833.0 billion (JPY +297.2 billion and +19.3% AER, +12.8% CER).

* Takeda’s Growth and Launch Products in the fiscal year ended March 31, 2024

GI: ENTYVIO, ALOFISEL, EOHILIA

Rare Diseases: TAKHZYRO, LIVTENCITY, ADZYNMA

PDT Immunology: Immunoglobulin products including GAMMAGARD LIQU